Abstract
Because of the key role of thrombin in the pathogenesis of acute coronary syndrome (ACS), the appropriate selection of antithrombotic therapy is important. Unfractionated herapin (UFH) has been the agent of choice for decades. Unfortunately, UFH has a number of limitations related to its pharmacokinetic and pharmacodynamic properties. Low molecular weight herapins (LMWHs) are attractive alternatives to UFH for several reasons, including predictable anticoagulation and ease of administration. Two LMWhs (dalteparin and enoxaparin) have been approved as alternatives to UFH in patients presenting with unstable angina and non-ST-segment elevation myocardial infarction. Randomized, controlled trials, in addition to open-label series, indicate that LMWH can safety be the agent of choice with or without glycoprotein llb/llla in the medical and upstream management of patients with ACS. Although the data are not definitive, several trials suggest that given intravenously, enoxaparin is safe as the sole antithrombotic agent in the catheterization laboratory.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 94-100 |
| Number of pages | 7 |
| Journal | Current Atherosclerosis Reports |
| Volume | 6 |
| Issue number | 2 |
| State | Published - Mar 2004 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Is the use of unfractionated heparin in acute coronary syndrome outmoded? / Chiquette, Elaine; Chilton, Robert J.
In: Current Atherosclerosis Reports, Vol. 6, No. 2, 03.2004, p. 94-100.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Is the use of unfractionated heparin in acute coronary syndrome outmoded?
AU - Chiquette, Elaine
AU - Chilton, Robert J
PY - 2004/3
Y1 - 2004/3
N2 - Because of the key role of thrombin in the pathogenesis of acute coronary syndrome (ACS), the appropriate selection of antithrombotic therapy is important. Unfractionated herapin (UFH) has been the agent of choice for decades. Unfortunately, UFH has a number of limitations related to its pharmacokinetic and pharmacodynamic properties. Low molecular weight herapins (LMWHs) are attractive alternatives to UFH for several reasons, including predictable anticoagulation and ease of administration. Two LMWhs (dalteparin and enoxaparin) have been approved as alternatives to UFH in patients presenting with unstable angina and non-ST-segment elevation myocardial infarction. Randomized, controlled trials, in addition to open-label series, indicate that LMWH can safety be the agent of choice with or without glycoprotein llb/llla in the medical and upstream management of patients with ACS. Although the data are not definitive, several trials suggest that given intravenously, enoxaparin is safe as the sole antithrombotic agent in the catheterization laboratory.
AB - Because of the key role of thrombin in the pathogenesis of acute coronary syndrome (ACS), the appropriate selection of antithrombotic therapy is important. Unfractionated herapin (UFH) has been the agent of choice for decades. Unfortunately, UFH has a number of limitations related to its pharmacokinetic and pharmacodynamic properties. Low molecular weight herapins (LMWHs) are attractive alternatives to UFH for several reasons, including predictable anticoagulation and ease of administration. Two LMWhs (dalteparin and enoxaparin) have been approved as alternatives to UFH in patients presenting with unstable angina and non-ST-segment elevation myocardial infarction. Randomized, controlled trials, in addition to open-label series, indicate that LMWH can safety be the agent of choice with or without glycoprotein llb/llla in the medical and upstream management of patients with ACS. Although the data are not definitive, several trials suggest that given intravenously, enoxaparin is safe as the sole antithrombotic agent in the catheterization laboratory.
UR - http://www.scopus.com/inward/record.url?scp=3142686084&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3142686084&partnerID=8YFLogxK
M3 - Article
C2 - 15023292
AN - SCOPUS:3142686084
VL - 6
SP - 94
EP - 100
JO - Current Atherosclerosis Reports
JF - Current Atherosclerosis Reports
SN - 1523-3804
IS - 2
ER -